Briggs, Emily
Kamal, Mohamed A.
Kosloski, Matthew P.
Linsmeier, Ian
Jusko, Natalie
Dolphin, Nancy
Chittenden, Jason
Simpson, Eric L.
Paller, Amy S.
Siegfried, Elaine C.
Shumel, Brad
Levit, Noah A.
Bansal, Ashish
Davis, John D.
Chapel, Sunny
Smith, David E.
Huniti, Nidal
Funding for this research was provided by:
Regeneron Pharmaceuticals
Sanofi
Article History
Received: 31 May 2023
Accepted: 27 September 2023
First Online: 11 December 2023
Declarations
:
: Briggs E, Chapel S, Linsmeier I: Amador Bioscience – previous employees; Regeneron Pharmaceuticals Inc. – former consultants. Jusko N, Dolphin N: Regeneron Pharmaceuticals Inc. – consultants. Kamal MA, Kosloski MP, Chittenden J, Shumel B, Bansal A, Davis JD: Regeneron Pharmaceuticals Inc. – employees and shareholders. Levit N, Huniti N: Regeneron Pharmaceuticals Inc. – former employees and shareholders. Simpson EL: Amgen, BMS, Chugai, Galderma, Genentech, Lilly, MedImmune, Sanofi-Regeneron Pharmaceuticals Inc., Tioga Pharmaceuticals, Vanda Pharmaceuticals – grants/research support; Anacor Pharmaceuticals, BMS, Galderma, Genentech, Medicis Pharmaceutical, Merck, Sanofi-Regeneron Pharmaceuticals Inc. – consultant. Paller AS: AbbVie, Applied Pharma Research, Dermavant, Eli Lilly, Incyte, Janssen, Krystal, UCB– Investigator; Aegerion Pharma, Azitra, BioCryst, Boehringer-Ingelheim, Bristol Myers Squibb, Castle Creek, Eli Lilly, Janssen, Krystal, LEO Pharma, Novartis, Regeneron, Sanofi/Genzyme, Seanergy, TWI Biotechnology, UCB – consultant with honorarium; AbbVie, Abeona Therapeutics, Catawba, Galderma, InMed – data and safety monitoring board. Siegfried EC: Dermavant, Eli Lilly, Pfizer, Regeneron Pharmaceuticals Inc., Verrica Pharmaceuticals – consultant; GSK, LEO Pharma, Novan – data and safety monitoring board; Eli Lilly, Janssen, Regeneron Pharmaceuticals Inc., Stiefel, Verrica Pharmaceuticals – Principal Investigator in clinical trials. Smith DE: None to report.